Background: An increased intake of magnesium might lower blood pressure (BP), yet evidence from clinical trials is inconsistent, perhaps as a result of small sample size or heterogeneity in study design.
E
xperimental and metabolic studies suggest that magnesium has a role in blood pressure (BP) regulation. 1 For example, in vitro studies have shown that magnesium influences cell membrane sodium pump activity, which in turn affects sodium-potassium transport across cell membranes, and subsequently vascular tone and reactivity. 2 In addition, clinical studies have demonstrated significant BP reductions with parenteral high-dose magnesium in patients with eclampsia and glomerulonephritis. 3, 4 This line of evidence, albeit indirect, suggests that an increased intake of magnesium might lower BP in otherwise healthy populations of free-living individuals.
In observational epidemiologic studies, several studies suggest an inverse association between dietary magnesium intake and BP. 5 However, this association is difficult to interpret because of the imprecision of dietary data and colinearity of magnesium intake with other dietary components. 6 In 1983, Dyckner and Wester 7 reported results from the first clinical trial of low-dose magnesium supplementation. Since then, a large number of supplement trials in humans have been published. 8 -32 Results of these trials have been inconsistent, perhaps because of small sample sizes or design limitations. The process of conducting a meta-analysis allows one to explore the basis of this heterogeneity and to estimate an effect size with precision. [33] [34] [35] [36] The objective of this meta-analysis was to determine whether magnesium supplementation reduces BP, to identify the dose-response relationship, and to determine trial characteristics associated with greatest BP reductions. 
Methods
We searched the English language literature for all reports on magnesium supplementation and BP in humans published before May 2001. Search strategies included: 1) a MEDLINE search using the medical subject headings magnesium and BP in clinical trials; 2) a review of reference lists from original research and review articles; and 3) a review of the authors' reference files. Thirty-one articles were identified.
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Our prespecified inclusion criteria were: 1) random allocation of participants, 2) use of magnesium supplementation alone as the active treatment, 3) presence of a control group, and 4) sufficient data to calculate the difference in BP change between the active treatment and control and the standard error of this difference. Twenty studies met the inclusion criteria. The major reasons for exclusion were: 1) nonrandomized treatment allocation, 2, 30 2) lack of a concurrent control group, 29 3) insufficient data to calculate the net change in BP or standard error, 30 -32 and 4) the combination of magnesium with other minerals that affect BP. 27, 28, 32 Two investigators (SJ and VS) independently abstracted the articles. Disagreements or uncertainties were adjudicated by consensus. From each article, the following data were abstracted: 1) characteristics of the study population including sample size, age, gender, proportion with hypertension, baseline magnesium intake, and BP level, 2) characteristics of the design including duration of intervention, treatment dose, and type of magnesium carrier, and 3) change in BP and associated variance. For crossover trials, we used mean BP during the control period as the baseline values.
Statistical Analysis
For parallel trials, net change in BP was calculated as the mean difference (magnesium supplementation minus control) of the change (follow-up minus baseline) in BP. For crossover trials, net change was calculated as the mean difference between the end of the magnesium supplementation and control periods. To calculate the pooled effects, each study was assigned a weight equivalent to the reciprocal of the variance of net change. For parallel trials in which the variance of paired differences during the trial was reported separately for several groups, we calculated variance for net change using standard methods. 35 Estimates of the mean effect of magnesium supplementation on BP and the corresponding 95% confidence intervals (CI) were calculated using both fixed effects and random effects models. Both approaches yielded similar patterns. Homogeneity of effect size across trials was tested by Q statistics. 34 Because there was substantial and significant heterogeneity in effect size across trials, we used meta-regression techniques to evaluate the impact of magnesium dose and other factors on study results. 35, 36 To examine potential publication bias, we plotted the sample sizes of the studies against their corresponding effect size. 35 
Results
Participant and design characteristics of the 20 clinical trials are presented in Table 1 . The trials were conducted between 1983 and 2001; the sample size varied from 13 to 461 participants, with a median of 30.5 participants per trial. The total number of participants was 1220. All of the trials were conducted in adults, with a range of mean ages from 23 to 65 years. Seventeen of the 20 trials included both men and women, whereas women were the sole participants in the remaining three trials. A crossover design was used in 8 trials, whereas a parallel arm design was used in the remaining 12 trials. Sixteen of the trials were double-blind, whereas the remaining 4 trials did not report information about blinding. The trials varied in length from 3 to 24 weeks, with a median duration of 8.5 weeks. The dose of magnesium supplementation in the active treatment group varied from 10 to 40 mmol/day, with a median of 15.4 mmol/day. Four trials were conducted in persons who were concurrently taking a diuretic. In the 20 trials, eight different compounds of magnesium were used (MgO, Mg aspartate, MgCl 2 MgOH 2 , Mg diglyceride, Mg citrate, Mg lactate, and Mg pidolate).
Systolic BP (SBP) decreased in the magnesium group compared to the control in 14 of the 20 trials; in 2 trials, the SBP reduction was statistically significant, whereas in 1 trial, magnesium significantly increased SBP (Fig. 1) . Overall, magnesium supplementation reduced SBP by 0.6 mm Hg (95% CI Ϫ2.2 to 1.0, P ϭ .051). Diastolic BP (DBP) decreased in the magnesium group compared to control in 14 of the 20 trials. In three trials, the DBP reduction was statistically significant (Fig. 1) . The pooled estimate of the effect of magnesium supplementation on DBP was a net decrease of 0.8 mm Hg (95% CI Ϫ2.1 to 0.5, P ϭ .142). The test for heterogeneity was highly significant both for SBP and DBP changes (P Ͻ .001), indicating that additional factors could impact the efficacy of magnesium in reducing BP.
When limiting the analysis to the 16 double-blind studies (excluding single-blinded studies), a 10 mmol/day increase in magnesium intake was associated with a decrease in SBP of 3.4 mm Hg (95% CI 0.6 to 6.1, P ϭ .02) and a decrease in DBP of 2.0 mm Hg (95% CI Ϫ0.9 to 5.0, P ϭ .18). Limiting the analysis to the 14 hypertensive trials (i.e., trials with average baseline SBP Ͼ140 mm Hg or DBP Ͼ90 mm Hg), magnesium (per 10 mmol/day) decreased SBP by 3.3 mm Hg (95% CI Ϫ0.1 to 6.8, P ϭ .06) and DBP by 2.3 mm Hg (95% CI Ϫ1.0 to 5.6, P ϭ .17). Table 2 summarizes the results of meta-regression analyses that examined the dose-response relationship between magnesium and BP (Fig. 2) . For each 10 mmol/day larger dose of magnesium SBP decreased by 4.3 mm Hg (95% CI 6.3 to 2.2, P Ͻ .001) and DBP by 2.3 mm Hg (95% CI 4.9 to 0.0, P ϭ .09). In addition, the effect of magnesium on SBP was stronger in trials with lower baseline SBP, although this effect was absent for DBP. The meta-regression model completely explained the residual heterogeneity for the effect of magnesium on SBP, but not on DBP (estimated between-study variation, ϭ 2.3 mm Hg). Other factors, including age, gender, trial design (crossover versus parallel), and duration were not significantly associated with magnesium efficacy.
The plot of sample size versus effect size was funnelshaped with little variation in the average effect size for the studies with larger sample size (not shown), thus minimizing the possibility that our findings could be explained by publication bias.
Discussion
To our knowledge, this is the first quantitative review of randomized trials that tested the effect of magnesium supplementation on BP. Although magnesium supplementation resulted in a small overall reduction in BP, there was an apparent dose-dependent effect of magnesium, specifically reductions of 4.3 mm Hg SBP and of 2.3 mm Hg DBP for each 10 mmol/day increase in magnesium dose.
The majority of trials included in this study (Ͼ70%) showed reductions in either SBP or DBP individually, yet were likely underpowered to detect small reductions in BP. Larger effect sizes would be expected in hypertensive persons, but the paucity of large trials in persons with hypertension might explain why significant findings in individual studies for SBP reduction was found only in trials of normotensive persons.
Our results indicate a greater efficacy that magnesium supplementation may have at higher doses. Such findings might explain why small trials that administered small doses of magnesium (10 to 15 mmol/day) failed to detect significant effects. Few studies were conducted in the higher dose range of magnesium (20 to 40 mmol/day). Properly designed and adequately powered trials at higher dose ranges need to be performed to confirm the inverse dose-response relationship that we detected.
One potential limitation is a lack of data on dietary intake of magnesium. In those trials that enrolled partici- pants diagnosed with hypertension, participants may have already increased dietary intake of magnesium-rich foods as a result of this diagnosis. Such modifications may have led to heterogeneity in the estimates of the magnesium-BP relationship. In addition, although the median amount of magnesium administered in these trials, 15 mmol/day, results in about a doubling of usual daily magnesium intake derived from diet (median ϳ12.5 mmol/day for men in the United States), it may not be a sufficiently large enough dose to produce a clinically relevant effect. Hence, as suggested by our pooled dose-response analysis, important BP-lowering effects may occur only at higher doses.
Other potential limitations include heterogeneity in study design, study participants, and in the type of magnesium supplement used. Absorption of magnesium supplements varies for different anions. Hence, some forms of administered magnesium may have had lower bioavailability, which would diminish the BP-lowering effect. Finally, our analysis contains only articles published in the English language. Studies in the English language literature may show a greater intervention effect than research that is never published or that is published in languages other than English. However, analysis of a funnel plot of study size did not show evidence of publication bias.
In summary, our meta-analysis detected significant, dose-dependent BP reductions from magnesium supplementation. This effect is consistent with experimental studies and with the effect of intravenous magnesium. However, there is still considerable uncertainty on the clinical utility of magnesium supplements. Adequately powered trials with sufficiently high doses of magnesium supplements need to be performed to confirm the inverse dose-response relationship observed in our study.
